NCT02063321

Brief Summary

The aim of the study is to find out prevalence of diabetic macular edema (DME) in patients with diabetes mellitus in Slovak Republic.The outcome of the project will be epidemiology survey, prevalence of wet form of Diabetic Macular Edema in relation to duration of diabetes, type of diabetes, treatment (insulin vs. OAD or combination) etc. and identification of prognostic factors leading to development of DME.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
762

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2012

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

February 11, 2014

Completed
3 days until next milestone

First Posted

Study publicly available on registry

February 14, 2014

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2015

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

February 14, 2014

Status Verified

February 1, 2014

Enrollment Period

2.8 years

First QC Date

February 11, 2014

Last Update Submit

February 12, 2014

Conditions

Keywords

DME, diabetic retinopathy, diabetes mellitus, epidemiology

Outcome Measures

Primary Outcomes (1)

  • Prevalence of Diabetic Macular Edema or clinically significant Diabetic Macular Edema

    Image of fundus taken in NIED securely sent via internet and electronic Clinical Report Form (eCRF) to ophthalmology reading center to assess stage and severity of potential retina damage, feedback to NIED within the stay of screened individual essential for further disease management

    Patients screened during hospitalization in National Institute of Endocrinology and Diabetology (NIED), usually in 10 days

Secondary Outcomes (5)

  • Patient´s structure with DME and clinically significant DME in terms of demography and anamnesis of diabetes

    Patients screened during hospitalization in NIED, usually in 10 days

  • Range of visual deterioration and occurence of blindness in relation to duration of diabetes

    Patients screened during hospitalization in NIED, usually in 10 days

  • Prognostic factors, which determine the occurence of DME using explorative analysis

    Patients screened during hospitalization in NIED, usually in 10 days

  • Range of visual deterioration and occurence of blindness in relation to type of diabetes

    Patients screened during hospitalization in NIED, usually in 10 days

  • Range of visual deterioration and occurence of blindness in relation to general treatment (insulin vs. OAD or combination therapy)

    Patients screened during hospitalization in NIED, usually in 10 days

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Adults regularly examined in National Institute of Endocrinology and Diabetology (NIED) for their severity and complications of diabetes will undergo a screening procedure using fundus camera to assess the back of the eye (fundus examination).

You may qualify if:

  • Adults ≥18 years treated in National Institute of Endocrinology and Diabetology
  • Patients diagnosed with Diabetes mellitus type I and type 2 respectively
  • Presence of Diabetes ≥10 years or patients with suspected visual impairment (duration of diabetes \<10 years)
  • Signed patient´s information and informed content

You may not qualify if:

  • Non-compliant patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Diabetic RetinopathyDiabetes Mellitus

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsEndocrine System DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Marta Ondrejkova, MD

    II. Eye Clinic SZU of F.D.Roosevelt Hospital, Banska Bystrica

    STUDY CHAIR
  • Monika Gajdosova, MD

    Oftal, s.r.o. Specialized Hospital for Ophthalmology, Zvolen

    STUDY CHAIR
  • Emil Martinka, MD

    Department of Diabetology of National Institute for Endocrinology and Diabetology, Lubochna

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Head of Diabetology Department

Study Record Dates

First Submitted

February 11, 2014

First Posted

February 14, 2014

Study Start

December 1, 2012

Primary Completion

September 1, 2015

Study Completion

December 1, 2015

Last Updated

February 14, 2014

Record last verified: 2014-02